Recursion Pharmaceuticals
RXRX
RXRX
328 hedge funds and large institutions have $1.55B invested in Recursion Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 109 increasing their positions, 90 reducing their positions, and 60 closing their positions.
Holders
328
Holders Change
-5
Holders Change %
-1.5%
% of All Funds
4.4%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
57
Increased
109
Reduced
90
Closed
60
Calls
$43.7M
Puts
$32.6M
Net Calls
+$11.1M
Net Calls Change
+$4.51M
Top Buyers
| 1 |
1
BlackRock
New York
|
$144M |
| 2 |
2
Vanguard Group
Malvern,
Pennsylvania
|
$183M |
| 3 |
3
Geode Capital Management
Boston,
Massachusetts
|
$39.4M |
| 4 |
4
First Trust Advisors
Wheaton,
Illinois
|
$9.51M |
| 5 |
5
Morgan Stanley
New York
|
$28.8M |
